Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels

Cardiology (Switzerland)

Volumn 76, Issue , 1989, Pages 55-61

  Larosa, John ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bile acid sequestrants; Cholestyramine; Colestipol; Coronary diseases; High density lipoprotein; Low density lipoprotein; Lowering; Plasma lipid levels; Prevention; Triglyceride

Indexed keywords

COLESTIPOL; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

CONSTIPATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY;

CHOLESTYRAMINE; CLINICAL TRIALS; COLESTIPOL; GASTROINTESTINAL DISEASES; HUMAN; HYPERLIPIDEMIA; POLYAMINES;

EID: 0024588352     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000174547     Document Type: Article

References (11)

1. Glueck CJ: Colestipol and probucol: Treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Ann Intern Med 1982;96:475-482.
2. Levy RI, Fredrickson DS, Stone NJ, et al: Cholestyramine in type II hyperlipoproteinemia-A double-blind trial. Ann Intern Med 1973;79:51-61.
3. Biel U, Crouse JR, Einarsson KL, et al: Effects of interruption of the enterohepatic circulation of bile acids on the transport of very-low-density lipoprotein triglycerides. Metabolism 1982;31: 438-444.
4. The Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
5. Witztum JL, Schonfeld G, Weidman SW, et al: Bile sequestrant therapy alters the composition of low-density and high-density lipoproteins. Metabolism 1979;28:221-229.
6. Vessby B, Kostner G, Lithell H, et al: Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp (a). Atherosclerosis 1982;44:61-71.
7. Brensike JF, Levy RI, Kelsy SF, et al: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI type II coronary intervention study. Circulation 1984;69:313-324.
8. Krauss RM, Williams PT, Brensike JJ, et al: Intermediate-density lipoprotein and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987;ii:62-65.
9. Dorr AE, Gundersen K, Schneider JC, et al: Colestipol hydrochloride in hypercholesterolemic patients. Effect on serum cholesterol and mortality. J Chronic Dis 1978;31:5-14.
10. The Lipid Research Clinic Program: The Lipid Research Clinics Coronary Primary Prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
11. Angelin B, Emarsson K: Cholestyramine in type Ila hyperlipoproteinemia-Is low-dose treatment feasible? Atherosclerosis 1981;38:33-38.